FI56681B - Foerfarande foer framstaellning av 2-amino-1,4-dihydropyridiner - Google Patents

Foerfarande foer framstaellning av 2-amino-1,4-dihydropyridiner

Info

Publication number
FI56681B
FI56681B FI656/73A FI65673A FI56681B FI 56681 B FI56681 B FI 56681B FI 656/73 A FI656/73 A FI 656/73A FI 65673 A FI65673 A FI 65673A FI 56681 B FI56681 B FI 56681B
Authority
FI
Finland
Prior art keywords
dihydropyridine
amino
frequency refrigeration
refrigeration
frequency
Prior art date
Application number
FI656/73A
Other languages
English (en)
Other versions
FI56681C (fi
Inventor
Horst Meyer
Friedrich Bossert
Wulf Vater
Kurt Stoepel
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Priority to FI772483A priority Critical patent/FI56682C/fi
Application granted granted Critical
Publication of FI56681B publication Critical patent/FI56681B/fi
Publication of FI56681C publication Critical patent/FI56681C/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38Nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Pyridine Compounds (AREA)
FI656/73A 1972-03-06 1973-03-02 Foerfarande foer framstaellning av 2-amino-1,4-dihydropyridiner FI56681C (fi)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FI772483A FI56682C (fi) 1972-03-06 1977-08-19 Foerfarande foer framstaellning av 2-amino-1,4-dihydropyridiner

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE2210674 1972-03-06
DE2210674A DE2210674C3 (de) 1972-03-06 1972-03-06 2-Amino-6-methyl-1,4-dihydropyridine, Verfahren zu ihrer Herstellung und sie enthaltende Arzneimittel

Publications (2)

Publication Number Publication Date
FI56681B true FI56681B (fi) 1979-11-30
FI56681C FI56681C (fi) 1980-03-10

Family

ID=5838026

Family Applications (1)

Application Number Title Priority Date Filing Date
FI656/73A FI56681C (fi) 1972-03-06 1973-03-02 Foerfarande foer framstaellning av 2-amino-1,4-dihydropyridiner

Country Status (27)

Country Link
US (1) US3867393A (fi)
JP (2) JPS5720306B2 (fi)
AT (1) AT324337B (fi)
AU (1) AU468090B2 (fi)
BE (1) BE796278A (fi)
BG (1) BG23213A3 (fi)
CA (1) CA983033A (fi)
CH (1) CH580590A5 (fi)
DD (1) DD107274A5 (fi)
DE (1) DE2210674C3 (fi)
DK (1) DK136214C (fi)
ES (1) ES412322A1 (fi)
FI (1) FI56681C (fi)
FR (1) FR2183675B1 (fi)
GB (1) GB1369401A (fi)
HK (1) HK44977A (fi)
HU (1) HU167087B (fi)
IE (1) IE37369B1 (fi)
IL (1) IL41665A (fi)
LU (1) LU67148A1 (fi)
NL (1) NL7303136A (fi)
NO (1) NO140977C (fi)
PL (1) PL89258B1 (fi)
RO (1) RO61193A (fi)
SE (1) SE384207B (fi)
YU (1) YU44873A (fi)
ZA (1) ZA731503B (fi)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3959296A (en) * 1972-06-10 1976-05-25 Bayer Aktiengesellschaft 1,4-Dihydropyridines
US3974278A (en) * 1973-07-12 1976-08-10 Bayer Aktiengesellschaft 1,4-Dihydropyridine esters
CH607848A5 (fi) * 1974-06-04 1978-11-30 Bayer Ag
DE2715182A1 (de) * 1977-04-05 1978-10-19 Bayer Ag 2-alkylenaminodihydropyridine, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
US4177278A (en) * 1977-04-05 1979-12-04 Bayer Aktiengesellschaft 2-Alkyleneaminodihydropyridines compounds, their production and their medicinal use
FI813460L (fi) * 1980-11-10 1982-05-11 Sandoz Ag Nya 4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-pyridinderivat deras framstaellningsfoerfarande och dessa innehaollande farmaceutiska kompositioner
DE3208628A1 (de) * 1982-03-10 1983-09-22 Bayer Ag, 5090 Leverkusen Neue verbindungen, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
EP0125803A3 (en) * 1983-04-27 1987-01-21 FISONS plc Pharmaceutically active dihydropyridines
US4603135A (en) * 1983-10-17 1986-07-29 Takeda Chemical Industries, Ltd. Substituted piperazinyl alkyl esters of 2-amino-4-aryl-1,4-dihydro-6-alkyl-3,5-pyridinedicarboxylates
GB8620880D0 (en) * 1986-08-29 1986-10-08 Pfizer Ltd Therapeutic agents
US4912239A (en) * 1987-11-13 1990-03-27 Dow Corning Corporation Method for stabilizing unsaturated organosilicone compositions
US5455253A (en) * 1992-10-20 1995-10-03 Zeneca Limited Heterocyclic derivatives
DE4430095A1 (de) * 1994-08-25 1996-02-29 Bayer Ag Verwendung von 6-Amino-1,4-dihydropyridinen als Arzneimittel zur Behandlung des zentralen Nervensystems und Verfahren zu ihrer Herstellung
DE4444860A1 (de) * 1994-12-16 1996-06-20 Bayer Ag Verwendung von 1,2-überbrückten 1,4-Dihydropyridinen als Arzneimittel
US20050203119A1 (en) * 2003-09-10 2005-09-15 Mitsunori Ono Dihydropyridine compounds for treating or preventing metabolic disorders
US20090012103A1 (en) * 2007-07-05 2009-01-08 Matthew Abelman Substituted heterocyclic compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3325505A (en) * 1965-02-24 1967-06-13 Smith Kline French Lab 4-cycloalkyl(or cycloalkenyl)-dihydropyridines
US3511847A (en) * 1967-02-07 1970-05-12 Smithkline Corp 2,6-di-lower alkyl - 1,4-dihydro - 4-(2-trifluoromethylphenyl) - 3,5 - pyridinedicarboxylic acid esters
DE1923990C3 (de) * 1969-05-10 1978-11-23 Bayer Ag Verfahren zur Herstellung von N-substituierten M-Dihydropyridin-S.S-dicarbonsäureestern
DE2013431C3 (de) * 1970-03-20 1979-12-20 Bayer Ag, 5090 Leverkusen 4-Azidophenyl-l,4-dihydropyridin-3,5-dicarbonsäureester
DE1963186C3 (de) * 1969-12-17 1979-02-15 Bayer Ag, 5090 Leverkusen Schwefelhaltige 1,4-Dihydropyridin-33-dicarbonsäureester
DE1963188A1 (de) * 1969-12-17 1971-06-24 Bayer Ag Neue Cyanphenyl-1,4-dihydropyridinderivate
ZA7152B (en) * 1970-01-24 1971-10-27 Bayer Ag New pharmaceutically active 1,4-dihydropyridines
DE2117571C3 (de) * 1971-04-10 1979-10-11 Bayer Ag, 5090 Leverkusen Unsymmetrische 1,4-Dihydropyridin-33-dicarbonsäureester, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Arzneimittel
DE2117572C3 (de) * 1971-04-10 1980-03-20 Bayer Ag, 5090 Leverkusen Unsymmetrische 1,4-Dihydropyridin ^-dicarbonsäureester, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Arzneimittel

Also Published As

Publication number Publication date
FI56681C (fi) 1980-03-10
FR2183675B1 (fi) 1976-12-03
BG23213A3 (fi) 1977-07-12
LU67148A1 (fi) 1973-05-22
NO140977B (no) 1979-09-10
YU44873A (en) 1982-02-25
SE384207B (sv) 1976-04-26
DD107274A5 (fi) 1974-07-20
JPS48103586A (fi) 1973-12-25
JPS5720306B2 (fi) 1982-04-27
HK44977A (en) 1977-09-09
AU468090B2 (en) 1975-03-27
NL7303136A (fi) 1973-09-10
CH580590A5 (fi) 1976-10-15
DE2210674B2 (de) 1980-09-04
HU167087B (fi) 1975-08-28
DK136214B (da) 1977-09-05
DK136214C (da) 1978-03-06
JPS5798265A (en) 1982-06-18
FR2183675A1 (fi) 1973-12-21
GB1369401A (en) 1974-10-09
ZA731503B (en) 1973-11-28
US3867393A (en) 1975-02-18
IE37369L (en) 1973-09-06
PL89258B1 (fi) 1976-11-30
IL41665A0 (en) 1973-05-31
BE796278A (fr) 1973-09-05
DE2210674C3 (de) 1981-09-24
RO61193A (fi) 1976-10-15
NO140977C (no) 1979-12-19
AT324337B (de) 1975-08-25
ES412322A1 (es) 1976-01-01
AU5287573A (en) 1975-03-27
IE37369B1 (en) 1977-07-06
CA983033A (en) 1976-02-03
DE2210674A1 (de) 1973-09-13
IL41665A (en) 1975-08-31

Similar Documents

Publication Publication Date Title
SE407579B (sv) Forfarande for framstellning av n-fosfonometylglycin
IT963505B (it) Procedimento per la fabbricazione di fibrille discontinue
NO139689C (no) Fremgangsmaate for fremstilling av lateks
FI56681B (fi) Foerfarande foer framstaellning av 2-amino-1,4-dihydropyridiner
NO140731C (no) Fremgangsmaate for fremstilling av dimetyleter
SE382053B (sv) Forfarande for framstellning av bifenylylalkanoylaminopyridiner
SE392609B (sv) Forfarande for framstellning av metanhaltiga gaser
FI55331B (fi) Foerfarande foer framstaellning av 1-hydroxi-2-pyridoner
IT963504B (it) Procedimento per la fabbricazione di fibrille discontinue
SE400768B (sv) Forfarande for framstellning av 2-fenyl-6-sulfamoyl-7-klor-1,2,3,4-tetrahydro-4-kinazolinon
SE393111B (sv) Forfarande for framstellning av d-2-halogen-6-metyl-8-substituerad - ergolin
SE380272B (sv) Forfarande for framstellning av n-fosfonmetylglycin
FI56830B (fi) Foerfarande foer framstaellning av asparaginylgrupper innehaollande biologiskt aktiva polypeptider
SE393808B (sv) Forfarande for framstellning av isomaltit
SE415355B (sv) Forfarande for framstellning av fosfonotioureider
NO136204C (no) Fremgangsm}te for fremstilling av proteaseinhibitoren plasminostreptin.
SE391717B (sv) Forfarande for framstellning av 4-aryl-5-aminoalkyl-4-oxazolin-2-oner
FI54861C (fi) Foerfarande foer framstaellning av emulsioner
FI55176B (fi) Foerfarande foer framstaellning av isopropylaminer
SE389862B (sv) Forfarande for framstellning av alfa-6-deoxitetracykliner
FI56846B (fi) Foerfarande foer framstaellning av estrogena 3-trialkylsilyletrar av 11beta-alkyl-17alfa-alkynylestra-1,3,5(10)-trien-3,17beta-dioler
FI56682B (fi) Foerfarande foer framstaellning av 2-amino-1,4-dihydropyridiner
TR17286A (tr) Ueretanlarin imaline mahsus usul
SE402286B (sv) Forfarande for framstellning av substituerade isokinoliner
SE408643B (sv) Forfarande for framstellning av morfantridiner